The much-awaited Indian Super League is finally here to soothe the football blues in India. The decision to conduct the tournament was announced in mid-late October as the organizers aim for a November 20 start. While that may be good news for football fans, the teams and other participants find themselves battling a logistical nightmare.
Not a Proper Pre-Season
Obviously, the Covid-19 pandemic has massively disrupted daily life. To keep the show going, teams and competitions worldwide have had to adapt to new rules and protocols. From following strict player and team bubbles to frequent testing and playing in empty stadiums, a lot has changed for teams, and more importantly, they are expected to adhere to them.
Now, let us imagine the same scenario for the Indian Super League - a competition that was announced a month before the official start date. The matches will take place in Goa across 3 stadiums in light of the pandemic; each of the 11 teams will have to share these venues as their home turfs.
All of this is above and beyond the internal logistics that need to be sorted among the teams. We are talking about establishing player bubbles and quarantine protocols, finding and securing team hotels - this takes precedent as the teams will be living at the same place for a good five months, establishing training routines, among other things.
A Crammed Schedule?
Traditionally, the ISL has followed the double round-robin format where each team plays the other side twice before making it to the semifinals and the final. This year too, with 11 sides in, the teams will be playing 20 games in total through November to March.
Ordinarily, with travelling and everything, players would get through this without a lot of problems. But given that they are restricted to merely three stadiums in Goa and not allowed to travel elsewhere, things will be different this time around.
Mental endurance will play an important role, just as much as physical form. Players will go through psychological toll and burnout; the team management will need to address this promptly.
It is, for this reason, we expect that the Indian Super League betting this season will be significantly different from its yesteryear counterparts. The odds may be much more competitive, in some cases, the odds offered on particular markets may not even seem worth it. In other words, expect the unexpected when it comes to football betting in the ISL.
But for the punters and veterans, it should be a matter of time before they figure out common markets to target throughout the league. The playing conditions will remain the same throughout which should add some sense of predictability.
But the League can Deliver
All things considered, the ISL this season promises to be a big hit. Atletico de Kolkata have merged with the Indian legends Mohun Bagan to give rise to a formidable team in the league - ATK Mohun Bagan. Bagan’s staunch rivals SC Ease Bengal have also joined the fray this season as league debutants.
This, in conjunction with the existing sides of Bengaluru FC, Chennaiyin, Goa, and others, do hold a great deal of potential in terms of entertainment and quality matches. There is plenty of local talent to follow, plenty of betting opportunities to capitalise on.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.